Myeloproliferative Neoplasms Update, Issue 1, 2019


Interview with Ruben A Mesa, MD

Track 1: Molecular pathogenesis of myeloproliferative neoplasms (MPNs)
Track 2: Cytokine activation and its association with the distinct symptomatology of MPNs
Track 3: Targeting the JAK-STAT pathway in myelofibrosis (MF) and polycythemia vera (PV)
Track 4: Case: A 66-year-old man with symptomatic primary MF with a CALR mutation receives ruxolitinib
Track 5: Clinical parameters to evaluate when considering treatment with ruxolitinib
Track 6: Discussing the complexities of allogeneic transplant with patients considering this intervention
Track 7: Clinical outcomes and complication rates for younger versus older patients undergoing transplant
Track 8: Counseling patients regarding the efficacy and side-effect profile of ruxolitinib
Track 9: Symptom improvement with ruxolitinib; dosing for patients with MF
Track 10: Management of anemia associated with ruxolitinib treatment
Track 11: Approach to dosing ruxolitinib for patients with MF and cytopenias
Track 12: Consideration of ruxolitinib treatment holidays and therapy reinitiation for patients with increased splenomegaly
Track 13: Treatment options for patients with MF and disease progression on ruxolitinib
Track 14: Clonal evolution and outcomes in MF after ruxolitinib discontinuation
Track 15: Therapeutic options for patients who experience disease progression on ruxolitinib
Track 16: Activity, tolerability and ongoing investigation of novel JAK inhibitors pacritinib, momelotinib and fedratinib in MF
Track 17: FDA clinical hold on fedratinib due to possible occurrences of Wernicke encephalopathy in patients on the JAKARTA-1 trial and recent lift of the hold
Track 18: Ongoing investigation of fedratinib in MF
Track 19: Clinical experience with pacritinib, momelotinib and fedratinib
Track 20: Toward identifying molecular predictors of response to pacritinib, momelotinib and fedratinib
Track 21: Case: A 64-year-old woman with ruxolitinib-refractory MF receives fedratinib on the Phase II JAKARTA-2 trial
Track 22: Therapeutic approach to MF that progresses to acute myeloid leukemia
Track 23: Investigation of the novel Bcl-2 inhibitor navitoclax in combination with ruxolitinib for patients with MF
Track 24: Clinical manifestations and treatment of PV
Track 25: Case: A 56-year-old woman with high-risk PV and an inadequate response to hydroxyurea receives ruxolitinib
Track 26: Risk stratification and treatment for patients with essential thrombocythemia (ET)

Interview with Aaron T Gerds, MD, MS

Track 1: Common misconceptions about MPNs
Track 2: Alterations of the JAK-STAT signaling pathway in MPNs
Track 3: Case: A 61-year-old woman with primary MF and mutations in JAK2, EZH2 and CALR receives ruxolitinib
Track 4: Prognostic significance of the JAK2, EZH2 and CALR mutations associated with MF
Track 5: Dosing and activity of ruxolitinib for MF
Track 6: Management of ruxolitinib-associated cytopenias and effect of ruxolitinib on disease pathogenesis
Track 7: Evolution of clinical research with the selective JAK2 inhibitor fedratinib for MF
Track 8: Association between fedratinib and thiamine levels; cytopenias associated with fedratinib
Track 9: Efficacy of fedratinib as second-line treatment for patients with disease progression on ruxolitinib
Track 10: Risks and benefits associated with pacritinib therapy
Track 11: Case: A 66-year-old man who presents with anemia is diagnosed with MF and a Type 1 CALR mutation
Track 12: Risk of infections associated with ruxolitinib
Track 13: Evaluation of ruxolitinib for the treatment of graft-versus-host disease
Track 14: Activity of the JAK1/2 inhibitor momelotinib in patients with MF
Track 15: Hepcidin suppression and improvement of anemia in patients with MF; effect of novel JAK inhibitors, including fedratinib and momelotinib
Track 16: Results of the SIMPLIFY 2 study evaluating momelotinib versus best available therapy for patients with MF previously treated with ruxolitinib
Track 17: Use of JAK inhibitors for rheumatoid arthritis
Track 18: Novel agents and approaches under investigation for MPNs
Track 19: Perspective on the potential role of venetoclax for patients with MPNs
Track 20: Case: A 75-year-old woman previously diagnosed with ET and a JAK2 V617F mutation is found to have disease transformation to PV on reassessment 12 years later
Track 21: Efficacy and side effects of the MDM2 antagonist idasanutlin in the treatment of PV
Track 22: Importance of maintaining hematocrit control in patients with PV
Track 23: Role of ruxolitinib for patients with PV
Track 24: Case: A 45-year-old woman with persistent headaches is diagnosed with ET and a JAK2 V617F mutation
Track 25: Therapeutic options for patients with ET
Track 26: Perspective on the need for aspirin for ET
Track 27: Role of interferon and PI3-kinase inhibitors in the treatment of MPNs
Ruben A Mesa, MD
Mays Cancer Center at UT Health
San Antonio MD Anderson
Mays Family Foundation Distinguished
University Presidential Chair
Professor of Medicine
San Antonio, Texas
Aaron T Gerds, MD, MS
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Staff, Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Neil Love, MD
Research To Practice
Miami, Florida